Emily Ehsan

Emily Ehsan

Auto-generated profile, based on publicly available information

Emily Ehsan

College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA, unmc.edu

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2024 in The American Journal of Dermatopathology
Verified
Journal Article
Closed access
EEEmily Ba Ehsan
Emily Ba Ehsan
EWErin X. Wei
Erin X. Wei
CGCorey J Georgesen
Corey J Georgesen
Importance: Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a severe cutaneous adverse reaction occurring 2 to 8 weeks after medication initiation. Diagnosis is clinical; RegiSCAR scoring includes biopsy “suggestive of DRESS,” undefined in the literature. Objective: This study correlates DRESS dermatopathology, culprit drugs, disease course, and outcome severity compared with maculopapular drug reactions (MDR). Methods: Between 2014 and 2023, a retrospective cohort study at a tertiary care institute reviewed 55 patients with DRESS, assessing demographics, culprit drug, illness course, and histopathology. Biopsies of 15 patients with DRESS and 15 MDR patients were graded by a predefined histopathological scoring system. Statistical analysis (significant P-value<0.05) included the Fisher exact probability, ANOVA, and correlation tests. Results: Among 55 patients with DRESS (mean age 50.13, 28 female/27 male), 15 (mean age 50.4, 7 female/8 male) had diagnostic biopsies. Compared with MDR patients, patients with DRESS exhibited significantly more interface dermatitis (P = 0.04), lichenoid dermatitis (P = 0.0007), pigment incontinence (P = 0.04), and periadnexal interface dermatitis (P = 0.002). MDR biopsies displayed perivascular inflammation and higher eosinophils than DRESS, trending toward significance. Conclusions: Key histopathologic features are interface dermatitis, periadnexal interface dermatitis, lichenoid dermatitis, pigment incontinence, and neutrophils dominance over eosinophils indicate DRESS clinically.

28 May 2026 in Global Surgical Education - Journal of the Association for Surgical Education
Verified
Journal Article
Closed access
BLBinh Le
Binh Le
LELily Ehsan
Lily Ehsan
OAONYEKACHI EMMANUEL Vision University ANYAGWA
ONYEKACHI EMMANUEL Vision University ANYAGWA
EEEmily Ehsan
Emily Ehsan
KBKeely Buesing
Keely Buesing
OSOlabisi Ololade Sheppard
Olabisi Ololade Sheppard

1 January 2026 in Case Reports in Infectious Diseases
Verified
Journal Article
Open access
EEEmily Ehsan
Emily Ehsan
ESEllie Staab
Ellie Staab
KGKatie Geelan-Hansen
Katie Geelan-Hansen
RHRichard Hankins
Richard Hankins
Introduction: Mucosal leishmaniasis (ML) is a rare, destructive, and recurrent protozoal infection caused by Leishmania species, most commonly Leishmania braziliensis . ML can develop months to years after initial cutaneous leishmaniasis (CL) and may lead to severe mucosal destruction if untreated. Case Presentation: We present a case of a 48‐year‐old healthy male from Venezuela with prior CL treated with intravenous meglumine antimoniate who subsequently developed progressive nasal symptoms consistent with ML. Initial therapy with oral fluconazole was ineffective, but treatment with miltefosine led to symptom resolution. The patient underwent four‐staged reconstructive surgeries with ENT. Thirty‐eight months later, the patient developed recurrent symptoms, and biopsy confirmed infection with L. braziliensis . He was subsequently treated with intravenous amphotericin B, which led to clinical improvement. Discussion: This case highlights the relapsing nature of ML, its potential for extensive mucosal damage, and the importance of a structured, long‐term care plan. This case in particular is unique given the extended delay before recurrence following miltefosine therapy. The high recurrence rate of L. braziliensis infections underscores the importance of vigilant long‐term follow‐up and consideration of systemic therapy. Multidisciplinary management is often necessary to optimize outcomes. Conclusion: Early recognition of ML, timely systemic therapy, structured multidisciplinary care, and adherence to a long‐term surveillance plan are critical to prevent mucosal destruction and manage relapses effectively. Extended surveillance may be warranted to detect late relapses in patients treated with newer or more effective agents.